Oncocyte Is Maintained at Buy by Needham
Oncocyte Is Maintained at Buy by Needham
Dow JonesApr 24 14:50 ET
Strong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial Efficiency
TipRanksApr 24 10:45 ET
Express News | OncoCyte Corp : Needham Raises Target Price to $4.25 From $3.60
Moomoo 24/7Apr 24 10:34 ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersImmunityBio (NASDAQ:IBRX) shares moved upwards by 32.0% to $6.52 during Tuesday's pre-market session. The company's market cap stands at $4.4 billion. Nuwellis (NASDAQ:NUWE) shares increased by
BenzingaApr 23 08:06 ET
Express News | Bio-Rad Laboratories Inc Reports 8.99% Passive Stake In Oncocyte Corp As Of April 15, 2024
Moomoo 24/7Apr 22 13:35 ET
Express News | Bio-Rad Laboratories Inc Reports 8.99% Passive Stake in OncoCyte Corp as of April 15 - SEC Filing
Moomoo 24/7Apr 22 13:31 ET
Oncocyte Price Target Maintained With a $4.00/Share by Stephens & Co.
Oncocyte Price Target Maintained With a $4.00/Share by Stephens & Co.
Dow JonesApr 17 10:26 ET
Express News | Stephens & Co. Reiterates Equal-Weight on OncoCyte, Maintains $4 Price Target
Moomoo 24/7Apr 17 10:16 ET
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic d
BenzingaApr 15 14:11 ET
Oncocyte Price Target Maintained With a $5.00/Share by Benchmark
Oncocyte Price Target Maintained With a $5.00/Share by Benchmark
Dow JonesApr 15 11:19 ET
Express News | Benchmark Reiterates Speculative Buy on OncoCyte, Maintains $5 Price Target
Moomoo 24/7Apr 15 11:09 ET
OncoCyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 96.08% Benchmark → $5 Reiterates Speculative Buy → Speculative Buy 11/13/2023 17.65% Piper Sand
BenzingaApr 15 11:06 ET
NXPL, MGRM and OCX Among Pre-market Losers
Seeking AlphaApr 15 08:21 ET
OncoCyte(OCX.US) Director Buys US$99,999.1 in Common Stock
$OncoCyte(OCX.US)$ Director Arno Andrew purchased 33,898 shares of common stock on Apr 11, 2024 at an average price of $2.95 for a total value of $99,999.1.Source: Announcement What is statement of ch
moomoo NewsApr 15 07:01 ET
OncoCyte(OCX.US) Officer Buys US$10,000.5 in Common Stock
$OncoCyte(OCX.US)$ Officer Riggs Josh purchased 3,390 shares of common stock on Apr 11, 2024 at an average price of $2.95 for a total value of $10,000.5.Source: Announcement What is statement of chang
moomoo NewsApr 15 06:57 ET
Oncocyte CEO Josh Riggs Buys $10,000 in Company Stock
InvestingApr 15 06:22 ET
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Shares of Medical Properties Trust, Inc. (NYSE:MPW) rose sharply in today's pre-market trading after the company announced that it sold its majority interest in Utah Hospitals. Medical Properties Tru
BenzingaApr 15 05:45 ET
OncoCyte Corp (OCX) Q4 2023 Earnings Call Transcript Highlights: Strategic Partnerships and ...
Yahoo FinanceApr 13 03:01 ET
Q4 2023 OncoCyte Corp Earnings Call
Yahoo FinanceApr 12 22:45 ET
12 Health Care Stocks Moving In Friday's After-Market Session
GainersQilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. The company's market cap stands at $40.7 million. Allarity Therapeutics (NASDAQ:ALLR
BenzingaApr 12 16:31 ET
No Data
No Data